Faeth Therapeutics (FTH) Other Accumulated Expenses (2020 - 2026)

Faeth Therapeutics (FTH) has 6 years of Other Accumulated Expenses data on file, last reported at $136000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses rose 81.33% year-over-year to $136000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $136000.0 (up 81.33% YoY) and the FY2025 annual result came in at $77000.0, down 38.89% from the prior year.
• Other Accumulated Expenses rose to $136000.0 in Q1 2026, from $77000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $221000.0 in Q4 2023 to a low of $75000.0 in Q1 2025.
• A 4-year average of $113000.0 and a median of $80000.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses slumped 42.99% — and 2026, when it soared 81.33%.
• Tracing FTH's Other Accumulated Expenses over 4 years: stood at $221000.0 in 2023, then tumbled by 42.99% to $126000.0 in 2024, then slumped by 38.89% to $77000.0 in 2025, then jumped by 76.62% to $136000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $136000.0 (Q1 2026), $77000.0 (Q4 2025), and $80000.0 (Q3 2025), per Business Quant data.